2024–2025 BNT162b2 KP.2 COVID-19 full season vaccine effectiveness from vaccine registries linked to administrative claims in two states: A cohort study in non-immunocompromised adults
Vaccine·
- DOI
- 10.1016/j.vaccine.2026.129009
- PMID
- 42594639
- PMCID
- —
- OpenAlex
- W7202358966
- Study type
- Cohort study
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
Findings support continued COVID-19 vaccine recommendations, demonstrating protection across the 2024-2025 season for adults including those with underlying medical conditions.
Structured evidence summary
Research question
The study estimated BNT162b2 KP.2 vaccine effectiveness against COVID-19-associated hospital admission, emergency department visits, and urgent care encounters among non-immunocompromised adults in two U.S. states during the 2024-2025 respiratory season.
Study design
A retrospective cohort study was conducted using linked vaccine registry and administrative claims data from Louisiana and California, with Cox proportional hazard models calculating time-varying vaccine exposure effectiveness against COVID-19-related encounters.
Population and setting
The cohort comprised 6,256,421 non-immunocompromised adults with continuous enrollment in contributing insurance plans, with 93% from California and 7% from Louisiana; 66% had at least one underlying medical condition.
Main findings
BNT162b2 KP.2 vaccination was associated with 37% effectiveness against COVID-19 hospitalization, 12% against ED/UC encounters, and 16% against combined ED/UC/hospitalization outcomes; protection was similar across age groups and underlying medical conditions.
Public-health relevance
Findings support continued COVID-19 vaccine recommendations, demonstrating protection across the 2024-2025 season for adults including those with underlying medical conditions.
Important limitations
The summary is limited to the supplied single-article abstract and metadata; the abstract does not explicitly state study limitations, and decision-grade interpretation would require review of the full original paper.
GIDS interpretation
This article represents published peer-reviewed research on 2024-2025 season COVID-19 vaccine effectiveness using U.S. administrative claims data; its discoverability supports ongoing evidence synthesis on vaccine performance against circulating variants.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 8 auditable classifier relationships to diseases, places, topics, and study design.